Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus-Reference-Cited by-同舟云学术

Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chamberlain Jeffrey M.¹,Sortino Katherine¹,Sethna Phiroze²,Bae Andrew²,Lanier Randall²,Bambara Robert A.¹,Dewhurst Stephen¹

Affiliation:

1. Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA

2. Chimerix, Durham, North Carolina, USA

Abstract

Human adenovirus (AdV) can cause fatal disease in immune-suppressed individuals, but treatment options are limited, in part because the antiviral cytidine analog cidofovir (CDV) is nephrotoxic. The investigational agent brincidofovir (BCV) is orally bioavailable, nonnephrotoxic, and generates the same active metabolite, cidofovir diphosphate (CDVpp).

Funder

Chimerix, Inc.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01925-18

Reference24 articles.

1. Emerging Infections: Adenovirus Infections in Transplant Recipients

2. Recombinant type Human mastadenovirus D85 associated with epidemic keratoconjunctivitis since 2015 in Japan

3. How I treat adenovirus in hematopoietic stem cell transplant recipients